Two-year follow-up of patients with heart failure with reduced ejection fraction receiving cardiac contractility modulation
Authors:
- M. A. VanderMVM. A. Vander
- E. A. LyasnikovaELE. A. Lyasnikova
- L. A. BelyakovaLBL. A. Belyakova
- M. A. TrukshinaMTM. A. Trukshina
- V. L. GalencoVGV. L. Galenco
- I. M. KimIKI. M. Kim
- T. A. LelyavinaTLT. A. Lelyavina
- M. Yu. SitnikovaMSM. Yu. Sitnikova
- M. L. AbramovMAM. L. Abramov
- D. S. LebedevDLD. S. Lebedev
- E. N. MikhaylovEME. N. Mikhaylov
Open Access
- 15 August 2020
- journal article
- research article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (7) , 3853
Abstract
Aim. To assess the 2-year prognosis of patients with heart failure with reduced ejection fraction (HFrEF) receiving cardiac contractility modulation (CCM).Material and methods. This single-center observational study included 55 patients (46 men, mean age 53±11 years) with NYHA class II-III HFrEF receiving optimal medical therapy, with sinus rhythm, QRS styear and every 6 months during the 2ndyear of observation. The primary composite endpoint was mortality and heart transplantation. Secondary composite endpoints included death, heart transplantation, paroxysmal ventricular tachycardia/ ventricular fibrillation, hospitalizations due decompensated HFResults.The one-year and two-year survival rate was 95% and 80%, respectively. Primary endpoint was observed in 20% of patients. NYHA class III and higher levels of N-terminal pro-brain natriuretic peptide (NTproBNP) were associated with unfavorable prognosis (p=0,014 and p=0,026, respectively). NTproBNP was an independent predictor of survival (p=0,018). CCM contributed to a significant decrease in hospitalizations due to decompensated HF (pstyear. The predictor for the secondary composite endpoint was NTproBNP (p=0,047).Conclusion. CCM is associated with a significant decrease in hospitalization rate due to decompensated HF. The 2-year survival rate of patients with NYHA class II-III HF receiving CCM was 80%. The NTproBNP level was an independent predictor of survival in patients receiving CMM for 2 years. Further longer-term studies of the CCM efficacy are required.Keywords
This publication has 13 references indexed in Scilit:
- Cardiac Contractility Modulation Improves Long-Term Survival and Hospitalizations in Heart Failure with Reduced Ejection FractionEuropean Journal of Heart Failure, 2019
- Cardiac Contractility Modulation in 2018Circulation, 2018
- A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility ModulationJACC: Heart Failure, 2018
- Cardiac contractility modulation in heart failure patients: Randomized comparison of signal delivery through one vs. two ventricular leadsJournal of Cardiology, 2017
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- Long-term survival with Cardiac Contractility Modulation in patients with NYHA II or III symptoms and normal QRS durationInternational Journal of Cardiology, 2016
- Efficacy and survival in patients with cardiac contractility modulation: Long-term single center experience in 81 patientsInternational Journal of Cardiology, 2015
- Long-term outcome of cardiac contractility modulation in patients with severe congestive heart failureEP Europace, 2011
- A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failureAmerican Heart Journal, 2011
- Impact of Cardiac Contractility Modulation on Left Ventricular Global and Regional Function and RemodelingJACC: Cardiovascular Imaging, 2009